Date: 2011-07-06
Type of information: Grant
Company: Ark Therapeutics (UK)
Investors:
Amount: €0.6 million
Funding type: grant
Planned used: Ark's Baculo-lentiviral system makes large scale lentivirus production much more efficient and cost-effective. The support from TEKES and ELY-centre will enable this technology to be established as a production platform within Ark's GMP manufacturing facility in Kuopio (Finland).
Others: Ark Therapeutics has been awarded a grant of up to €0.4 million from Finnish Funding Agency for Technology and Innovation (TEKES) to support the further development of Ark's proprietary lentiviral vector production technology using baculoviruses ("Baculo-lentiviral") to achieve the scale and GMP quality required for clinical use.
Ark Therapeutics has also been awarded a €0.2 million grant from Finnish governmental organization Centre for Economic Development, Transport and the Environment (ELY-centre) to progress validation work in its GMP3 manufacturing facility in Kuopio (Finland).
Therapeutic area: Technology - Services
